Zydus Lifesciences Ltd.

Zydus Cadila has received the final approval from the USFDA to market Acyclovir Tablets in the strengths of 400 mg and 800 mg. The drug falls under the anti-viral segment. The estimated sales in 2014 for Acyclovir Tablets is $55.8 million, as per IMS.

The group now has 95 approvals and has so far filed 249 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.